Recurrent fusions of ETS genes are considered driving mutations in a diverse array of
cancers, including Ewing's sarcoma, acute myeloid leukemia, and prostate cancer. We …

Rearrangements, or gene fusions, involving the ETS family of transcription factors are
common driving events in both prostate cancer and Ewing sarcoma. These rearrangements …

The TMPRSS2-ERG fusion, present in approximately 50% of prostate cancers, is less
common in prostatic intraepithelial neoplasia (PIN), raising questions about whether …

Recurrent gene fusions involving oncogenic ETS transcription factors (including ERG, ETV1,
and ETV4) have been identified in a large fraction of prostate cancers. The most common …

TMPRSS2: ERG gene fusions and PTEN deletions are the most common genomic
aberrations in prostate cancer. Recent work has suggested that the TMPRSS2: ERG fusion …

Approximately 50% of prostate cancers are associated with gene fusions of the androgen-
regulated gene TMPRSS2 to the oncogenic erythroblast transformation-specific (ETS) …

Although common in hematologic and mesenchymal malignancies, recurrent gene fusions
have not been well characterized in epithelial carcinomas. Recently, using a novel …

Chromosomal rearrangements that result in high level expression of ETS gene family
members are common events in human prostate cancer. Most frequently, the androgen …

Purpose: The expression of the ETS-related gene (ERG) is low or undetectable in benign
prostate epithelial cells. High prevalence of ERG overexpression in prostate cancer cells …

Recently, gene fusions between the androgen responsive gene TMPRSS2 and members of
the ETS-family of DNA-binding transcription factor genes were found in prostate cancer …